PRADA: Do Cardioprotective Drugs During Adjuvant Therapy For Breast Cancer Improve CV Outcomes?
Dec 19, 2023
Cardioprotective drugs during adjuvant therapy for early-stage breast cancer do not protect against long-term decline in cardiac function, according to new data from the PRADA trial presented May 16 during ACC.21 and simultaneously published in Circulation. In the single center, double-blind trial, Siri Lagethon Heck, MD, PhD, et al., assessed the long-term impact of candesartan cilexetil (32 mg), metoprolol succinate (100 mg), a combination, or a placebo on preventing a decrease in cardiac function and myocardial injury. Using a 2×2 factorial design, 120 patients with early-stage breast cancer receiving anthracycline-containing chemotherapy after surgery were randomized 1:1:1:1 to the four treatment arms. Cardiac MRI was performed at the start of the study and after a median of 23 months.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…